```html

Disseminated Candidiasis – A Complete Patient Guide

Overview

Disseminated candidiasis (also called invasive or systemic candidiasis) is a serious fungal infection that occurs when the yeast Candida spreads from its usual sites (mouth, gut, vagina, or skin) into the bloodstream and other internal organs such as the heart, brain, kidneys, eyes, and bones. While Candida species are normal inhabitants of the human microbiome, they become pathogenic when the immune system is compromised or when the normal microbial balance is disrupted.

Who it affects

• Adults with weakened immunity – e.g., patients receiving chemotherapy, organ‑transplant recipients, or those with advanced HIV/AIDS.
• Critically ill patients in intensive‑care units (ICUs) on broad‑spectrum antibiotics, central venous catheters, or receiving parenteral nutrition.
• People with uncontrolled diabetes mellitus, especially with diabetic ketoacidosis.
• Those on prolonged corticosteroid therapy or other immunosuppressants (e.g., biologics for autoimmune disease).

Prevalence

In the United States, invasive candidiasis accounts for roughly 40 % of all bloodstream fungal infections, with an estimated 46,000–50,000 cases each year and a mortality rate of 30–40 % despite treatment (CDC, 2023). The incidence is rising in developing countries as intensive‑care services expand and use of immunosuppressive therapies increases.

Symptoms

Symptoms vary widely because the infection can involve many organ systems. Below is a comprehensive list organized by the most common clinical presentations.

General / systemic symptoms

• Fever – often persistent, may be refractory to standard antibiotics.
• Chills or rigors
• Fatigue, malaise
• Night sweats
• Weight loss (unintentional, over weeks)

Cardiovascular

• Endocarditis: new heart murmur, embolic phenomena, heart failure.
• Mycotic aneurysm: localized pain, pulsatile mass.

Central nervous system

• Headache, altered mental status, seizures.
• Focal neurologic deficits if brain abscesses develop.

Renal

• Flank pain, hematuria, decreased urine output.
• Renal insufficiency evident on labs.

Ocular

• Redness, pain, blurry vision, floaters – signs of endogenous endophthalmitis.

Hepatobiliary

• Upper‑right abdominal pain, jaundice, elevated liver enzymes.

Skeletal / joint

• Bone pain, swelling, limited range of motion – osteomyelitis or septic arthritis.

Skin

• Rash that may appear as erythematous papules, vesicles, or tender nodules (often on trunk or extremities).

Causes and Risk Factors

Primary cause: Overgrowth of Candida species (most commonly C. albicans, but C. glabrata, C. tropicalis, C. parapsilosis, C. krusei are increasingly implicated) that gains access to the bloodstream. Entry routes include:

1. Disruption of mucosal barriers – e.g., gastrointestinal ulceration, oral thrush, or vulvovaginal candidiasis.
2. Intravascular devices – central venous catheters, arterial lines, dialysis catheters.
3. Surgical sites – especially abdominal or cardiac surgery.
4. Parenteral nutrition solutions that become contaminated.

Key risk factors

• Neutropenia (<1500 neutrophils/µL) – common after chemotherapy.
• Prolonged (>7 days) broad‑spectrum antibiotics that suppress normal bacterial flora.
• Solid‑organ or hematopoietic stem‑cell transplantation.
• Chronic corticosteroid use (≥20 mg prednisone daily for ≥2 weeks).
• Diabetes mellitus with HbA1c >8 %.
• Severe mucosal trauma – e.g., burns, radiation therapy.
• Genetic immune defects (e.g., chronic granulomatous disease).

Diagnosis

Because symptoms are non‑specific, a high index of suspicion is essential. Diagnosis combines clinical assessment, laboratory testing, and imaging.

Laboratory tests

• Blood cultures – gold standard; yields organism in ~50 % of cases, higher with ≥2 sets drawn from separate sites.
• Serum (1→3)-β‑D‑glucan (BDG) – fungal cell‑wall component; elevated levels support invasive candidiasis, though false‑positives can occur (hemodialysis, certain antibiotics).
• Candida antigen/antibody assays – limited utility in acute settings.
• Complete blood count (CBC) – often shows leukocytosis or neutropenia.
• Comprehensive metabolic panel – assesses organ dysfunction (renal, hepatic).

Imaging studies

• Trans‑esophageal echocardiography (TEE) – detects endocarditis or intracardiac vegetations.
• CT or MRI of abdomen/pelvis – identifies hepatic, splenic, renal lesions or abscesses.
• Fundoscopic exam or ocular ultrasound – screens for endophthalmitis.
• Head CT/MRI – indicated if neurologic signs emerge.

Microbiologic confirmation from other sites

If blood cultures are negative but suspicion remains, cultures from urine, sputum, cerebrospinal fluid, or tissue biopsies can yield the organism.

Diagnostic criteria (IDSA 2022)

The Infectious Diseases Society of America (IDSA) recommends classifying cases as:

1. Proven invasive candidiasis – a sterile site culture positive for Candida + compatible clinical picture.
2. Probable invasive candidiasis – negative blood cultures but presence of a risk factor, compatible imaging, and a positive non‑blood culture (e.g., peritoneal fluid).
3. Possible invasive candidiasis – clinical signs without microbiologic proof; treatment decisions rely on risk assessment.

Treatment Options

Therapy should begin promptly—often before definitive culture results—when invasive candidiasis is strongly suspected.

Antifungal Medications

Drug Class	Common Agent(s)	Usual Dose (IV)	Notes
Echinocandins	Caspofungin, Micafungin, Anidulafungin	70 mg loading, then 50 mg daily (caspofungin) etc.	First‑line for most adults; safe in renal/hepatic impairment.
Azoles	Fluconazole, Voriconazole, Posaconazole	Fluconazole 800 mg loading, then 400 mg daily	Effective for C. albicans but not for azole‑resistant species (e.g., C. glabrata).
Polyenes	Amphotericin B deoxycholate, Liposomal Amphotericin B	Liposomal 3–5 mg/kg daily	Reserved for severe disease or when other agents contraindicated; monitor renal function.

**Treatment duration**:* Minimum 2 weeks after the last positive culture and after resolution of fever, plus at least 1 week after catheter removal. Deep‑seated infections (endocarditis, osteomyelitis, CNS) may require 6–12 weeks.

Adjunctive Measures

• Removal of infected indwelling devices (central lines, urinary catheters) whenever feasible.
• Source control – surgical drainage of abscesses, debridement of infected tissue.
• Control of underlying conditions – tight glycemic control in diabetics, reduction of immunosuppressive dose when possible.

Special Situations

• Pregnancy – echinocandins are category B; fluconazole high‑dose is avoided after the first trimester.
• Pediatric patients – dosing based on weight; micafungin and liposomal amphotericin B are commonly used.
• Renal failure – echinocandins do not require dose adjustment; liposomal amphotericin B preferred over deoxycholate.

Living with Disseminated Candidiasis

Even after successful treatment, many patients need ongoing management to prevent relapse.

Medication adherence

• Keep a medication diary or use a phone reminder.
• Never skip doses—even if you feel better.
• Report side‑effects (e.g., liver enzyme elevations, kidney problems) promptly.

Monitoring

• Regular follow‑up labs: CBC, renal & liver panels, and serum BDG if previously elevated.
• Repeat imaging (CT, echocardiogram) as directed to confirm resolution of organ lesions.
• Eye examination within 1–2 weeks of diagnosis if bloodstream infection was documented.

Lifestyle adjustments

• Maintain optimal blood sugar (target HbA1c <7 %).
• Stay hydrated; adequate fluid intake supports kidney function.
• Good oral hygiene—brush twice daily, use antifungal mouthwash if prescribed.
• Limit alcohol and avoid smoking, which further impair immune defenses.
• Balanced diet rich in protein, vitamins A, C, D, and zinc to support immunity.

Psychosocial support

Chronic illness can cause anxiety and depression. Seek counseling, join support groups, and discuss mental‑health concerns with your provider.

Prevention

Because most cases arise in health‑care settings, prevention focuses on infection‑control practices.

• Hand hygiene – Alcohol‑based rubs or soap-and‑water before/after patient contact.
• Catheter stewardship – Insert central lines only when essential, use maximal sterile barrier technique, and remove as soon as clinically possible.
• Antibiotic stewardship – Limit duration of broad‑spectrum antibiotics; de‑escalate based on cultures.
• Antifungal prophylaxis – Recommended for high‑risk neutropenic patients (e.g., fluconazole 400 mg daily) per IDSA guidelines.
• Glycemic control – Monitor blood glucose at least twice daily in diabetic or critically ill patients.
• Environmental measures – Keep moist areas (skin folds, perineum) dry; change dressings promptly.

Complications

If untreated or inadequately treated, disseminated candidiasis can lead to life‑threatening sequelae:

• Septic shock – profound hypotension, multi‑organ failure.
• Endocarditis – valve destruction, embolic stroke.
• Endophthalmitis – permanent vision loss.
• Renal failure – due to renal infarcts or drug toxicity.
• Hepatic abscesses – may require percutaneous drainage.
• Central nervous system infection – cerebral abscesses, meningitis.
• Osteomyelitis or septic arthritis – chronic pain, functional impairment.

When to Seek Emergency Care

---

Sources: CDC. Invasive Candidiasis Surveillance Report, 2023; IDSA Clinical Practice Guidelines for Management of Candidiasis (2022); Mayo Clinic. Disseminated candidiasis overview; NIH National Institute of Allergy and Infectious Diseases; WHO Fungal Infection Fact Sheet; Cleveland Clinic – Systemic Candidiasis.

```